Literature DB >> 7120075

Degradation of melphalan in aqueous solutions--influence of human albumin binding.

H Ehrsson, U Lönroth.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1982        PMID： 7120075     DOI： 10.1002/jps.2600710729

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN： 0022-3549            Impact factor:   3.534


× No keyword cloud information.
  10 in total

1.  Determination of melphalan in human plasma by UPLC-UV method.

Authors:  Liusheng Huang; Vincent Cheah; Danna Chan; Florence Marzan; Christopher C Dvorak; Francesca T Aweeka; Janel Long-Boyle
Journal:  Cancer Chemother Pharmacol       Date:  2019-02-13       Impact factor: 3.333

2.  Comparative brain and plasma pharmacokinetics and anticancer activities of chlorambucil and melphalan in the rat.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Pharmacokinetic and metabolic studies of busulfan in rat plasma and brain.

Authors:  M Hassan; H Ehrsson; I Wallin; S Eksborg
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1988 Oct-Dec       Impact factor: 2.441

4.  Renal clearance and protein binding of melphalan in patients with cancer.

Authors:  P A Reece; H S Hill; R M Green; R G Morris; B M Dale; D Kotasek; R E Sage
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

5.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.

Authors:  H Ehrsson; S Eksborg; A Osterborg; H Mellstedt; A Lindfors
Journal:  Med Oncol Tumor Pharmacother       Date:  1989

7.  Pharmacokinetics of peptichemio in myeloma patients: release of m-L-sarcolysin in vivo and in vitro.

Authors:  H Ehrsson; R Lewensohn; I Wallin; M Hellström; G Merlini; B Johansson
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

Review 8.  Stability of solutions of antineoplastic agents during preparation and storage for in vitro assays. General considerations, the nitrosoureas and alkylating agents.

Authors:  A G Bosanquet
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  The pharmacokinetic advantages of isolated limb perfusion with melphalan for malignant melanoma.

Authors:  R N Scott; D J Kerr; R Blackie; J Hughes; G Burnside; R M MacKie; D S Byrne; A J McKay
Journal:  Br J Cancer       Date:  1992-07       Impact factor: 7.640

10.  The effect of systemic hyperthermia on melphalan pharmacokinetics in mice.

Authors:  D J Honess; J Donaldson; P Workman; N M Bleehen
Journal:  Br J Cancer       Date:  1985-01       Impact factor: 7.640
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.